CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis
Large-cohort CSF proteomics from the Mann Lab identifies a 22-protein panel distinguishing MS from related diseases
Clinical Scorecard: CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis
At a Glance
Category Detail
Condition Multiple Sclerosis (MS) Key Mechanisms Identification of protein signatures related to B-cell activity, axonal damage, and immune signaling. Target Population Patients with multiple sclerosis, particularly those lacking classical biomarkers. Care Setting Neurology clinics and laboratories utilizing cerebrospinal fluid analysis.
Key Highlights
Identification of a 22-protein panel that improves MS diagnosis. High-throughput mass spectrometry used to analyze over 1,500 proteins per CSF sample. Proteomic patterns may provide prognostic information regarding long-term disability outcomes. Guideline-Based Recommendations
Diagnosis
Utilize a 22-protein panel for improved differentiation of MS from other inflammatory diseases. Management
Incorporate targeted mass spectrometry assays into routine laboratory workflows. Monitoring & Follow-up
Assess CSF proteomic patterns at diagnosis for prognostic insights. Risks
Diagnosis may be delayed in patients lacking oligoclonal bands. Patient & Prescribing Data
Individuals with diverse neurological disorders, particularly those suspected of having MS.
Proteomic analysis may guide treatment decisions based on disease progression.
Clinical Best Practices
Combine CSF analysis with advanced mass spectrometry for accurate diagnosis. Monitor proteomic changes over time to assess disease progression. Related Resources & Content
